$889.12-18.87 (-2.08%)
McKesson Corporation provides healthcare services in the United States and internationally.
McKesson Corporation in the Healthcare sector is trading at $889.12 with a market capitalization of $100.1B. Wall Street consensus targets $980.73 (15 analysts), implying a +10.3% move over the next 12 months. The stock is currently 11% below its 52-week high of $999.00, remaining 5.6% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $96.30B↓ | $106.16B↑ | $103.15B↑ | $97.83B↑ | $90.82B |
| Gross Profit | $4.04B↑ | $3.69B↑ | $3.54B↑ | $3.28B↓ | $3.64B |
| Operating Income | $2.25B↑ | $1.66B↑ | $1.47B↑ | $1.08B↓ | $1.66B |
| Net Income | $1.68B↑ | $1.19B↑ | $1.11B↑ | $784.00M↓ | $1.26B |
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions...

CVS Health is advancing Aetna's profitability turnaround, supported by stronger Health Care Benefits results, an improved MBR and operational initiatives.

Reuters reported that McKesson Corporation (NYSE:MCK) said it would buy privately held Precision Medicine Group in a deal valued at about $2.25 billion as part of a “years-long effort to strengthen its higher-growth businesses.” McKesson has been reshaping its portfolio by exiting non-core assets and streamlining its operations while investing in businesses such as oncology […]

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

McKesson has outpaced the healthcare sector, and analysts remain highly optimistic about the stock’s outlook.
Academic risk and quality models computed from MCK's own filings and price history, not from analyst opinion.
Mixed: 6 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z above the 2.99 safe threshold, so the model puts bankruptcy risk in its lowest band.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, above the current 27.4% reading.
Fama-French 5-factor market beta. The five factors explain 13% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-09-08.